Hospital
Regents Univ of Calif Los Angeles
Regents Univ of Calif Los Angeles was paid $41.47M by Medicaid between Jan 2018 and Dec 2024, across 496 billing codes. Its largest line is J1561, Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg — 6.8% of everything it billed.
33Billing provider infoREGENTS UNIV OF CALIF LOS ANGELES
LOS ANGELES, CA 90095
LOS ANGELES, CA 90095
33aNPI1902803315assigned 06/30/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$41.47M
24GClaims1,288,715
24DCodes billed496
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#73 of 410
Median peer was paid$6.90M
This provider vs. median6.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 152,062 | $3.75M | |
| 2019 | 134,920 | $3.61M | |
| 2020 | 125,929 | $3.67M | |
| 2021 | 146,834 | $5.33M | |
| 2022 | 198,855 | $6.92M | |
| 2023 | 262,683 | $9.09M | |
| 2024incomplete | 267,432 | $9.10M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 6.8% | 5,340 | 1,500 | $2.82M |
| J9271 | Injection, pembrolizumab, 1 mg | 6.8% | 1,184 | 981 | $2.81M |
| 0450 | Emergency room services | 5.6% | 43,796 | 37,233 | $2.33M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 4.8% | 54,630 | 41,051 | $2.01M |
| 80053 | Comprehensive metabolic panel | 3.0% | 54,576 | 39,507 | $1.25M |
| 78815 | Positron emission tomography (PET) for limited area imaging | 2.4% | 1,412 | 1,388 | $993K |
| 0949 | 2.3% | 27,433 | 21,012 | $949K | |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | 2.1% | 315 | 200 | $889K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 2.1% | 1,028 | 990 | $871K |
| 93325 | 1.7% | 4,399 | 4,125 | $688K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.6% | 3,040 | 2,952 | $669K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.6% | 3,331 | 3,181 | $662K |
484 more codes
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | 1.6% | 2,367 | $659K |
| J0897 | Injection, denosumab, 1 mg | 1.5% | 1,452 | $633K |
| 0710 | 1.5% | 3,254 | $611K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 11,227 | $520K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.2% | 4,249 | $518K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.2% | 6,057 | $490K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 54,481 | $451K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.1% | 16,191 | $442K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.0% | 14,646 | $427K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.0% | 8,167 | $425K |
| 99283 | Emergency room visit (moderate) | 1.0% | 3,029 | $419K |
| J3490 | Unclassified drugs | <1% | 26,900 | $407K |
| 87497 | <1% | 8,920 | $402K | |
| 99285 | Emergency room visit (most serious) | <1% | 1,762 | $397K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 8,831 | $394K |
| Q5118 | Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | <1% | 446 | $377K |
| 0471 | <1% | 3,653 | $351K | |
| 80197 | <1% | 20,281 | $327K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 10,245 | $322K |
| 0370 | <1% | 3,378 | $318K | |
| 93320 | <1% | 2,373 | $307K | |
| 0762 | <1% | 192 | $291K | |
| 0761 | <1% | 10,281 | $289K | |
| 99284 | Emergency room visit (serious) | <1% | 4,103 | $286K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 6,376 | $278K |
| J0178 | Injection, aflibercept, 1 mg | <1% | 781 | $276K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 7,298 | $258K |
| 74178 | <1% | 1,029 | $248K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,346 | $233K |
| 87799 | <1% | 5,140 | $232K | |
| Z7500 | <1% | 6,639 | $225K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,602 | $222K |
| 93308 | <1% | 1,908 | $221K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 5,499 | $221K |
| 83735 | <1% | 30,218 | $201K | |
| J9312 | Injection, rituximab, 10 mg | <1% | 64 | $195K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,764 | $191K |
| 83880 | <1% | 7,626 | $179K | |
| 80051 | <1% | 20,179 | $177K | |
| J9299 | Injection, nivolumab, 1 mg | <1% | 50 | $175K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,833 | $175K |
| Q3014 | Telehealth originating site facility fee | <1% | 16,808 | $168K |
| 0250 | <1% | 44,168 | $161K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 543 | $160K |
| 71250 | <1% | 1,274 | $159K | |
| 88185 | <1% | 506 | $155K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 9,911 | $154K |
| 85027 | <1% | 29,226 | $152K | |
| 81001 | <1% | 29,114 | $141K | |
| 0258 | <1% | 14,476 | $140K | |
| 86850 | <1% | 10,064 | $133K | |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 1,193 | $129K |
| 99000 | <1% | 27,893 | $128K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,812 | $127K |
| 86900 | <1% | 10,437 | $119K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 10,405 | $118K |
| 96415 | <1% | 3,490 | $118K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,404 | $117K |
| 0301 | <1% | 3,203 | $115K | |
| Z5942 | <1% | 726 | $115K | |
| 84100 | <1% | 23,438 | $115K | |
| 74183 | <1% | 275 | $113K | |
| 0360 | <1% | 669 | $112K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 943 | $110K |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | <1% | 176 | $109K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,269 | $107K |
| 86833 | <1% | 3,309 | $106K | |
| 86832 | <1% | 3,304 | $103K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,846 | $102K |
| 71045 | Radiologic examination, chest; single view | <1% | 7,840 | $102K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,488 | $102K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,824 | $101K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,733 | $98K |
| 86481 | <1% | 1,656 | $96K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 779 | $93K |
| 87631 | <1% | 2,108 | $91K | |
| 99199 | Unlisted special service, procedure or report | <1% | 2,415 | $91K |
| 0760 | <1% | 3,232 | $89K | |
| 82565 | <1% | 20,907 | $87K | |
| 96367 | <1% | 3,305 | $87K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,095 | $84K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,170 | $83K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,768 | $82K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,006 | $81K |
| J2778 | Injection, ranibizumab, 0.1 mg | <1% | 274 | $80K |
| J9022 | Injection, atezolizumab, 10 mg | <1% | 36 | $79K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 5,244 | $78K |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 297 | $77K |
| 86901 | <1% | 10,401 | $77K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 318 | $76K |
| 80076 | <1% | 7,139 | $76K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,159 | $76K |
| 80061 | Lipid panel | <1% | 8,520 | $76K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 761 | $74K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 383 | $74K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,949 | $73K |
| 82947 | <1% | 21,363 | $71K | |
| 84484 | <1% | 7,864 | $71K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 7,082 | $70K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,357 | $69K |
| 0636 | <1% | 420 | $67K | |
| 84703 | <1% | 6,345 | $66K | |
| H1001 | Prenatal care, at-risk enhanced service; antepartum management | <1% | 1,086 | $65K |
| 83970 | <1% | 2,169 | $63K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 4,389 | $61K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 8,176 | $60K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 6,923 | $60K |
| 85610 | <1% | 10,956 | $60K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 3,227 | $59K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,735 | $59K |
| 93321 | <1% | 714 | $58K | |
| 82105 | <1% | 1,934 | $58K | |
| 83615 | <1% | 8,239 | $57K | |
| 96417 | <1% | 2,874 | $57K | |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 71 | $57K |
| 70486 | <1% | 372 | $56K | |
| 94729 | <1% | 1,158 | $54K | |
| 96376 | <1% | 1,616 | $53K | |
| 94010 | <1% | 1,401 | $51K | |
| 82784 | <1% | 3,832 | $51K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,099 | $51K |
| 93971 | <1% | 646 | $50K | |
| 93296 | <1% | 607 | $50K | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,698 | $49K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 831 | $49K |
| 99070 | <1% | 982 | $48K | |
| Z1034 | <1% | 668 | $48K | |
| 82728 | <1% | 4,006 | $46K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 811 | $46K |
| 86140 | <1% | 6,051 | $45K | |
| 87040 | <1% | 2,962 | $44K | |
| 76830 | Ultrasound, transvaginal | <1% | 801 | $43K |
| 83605 | <1% | 3,840 | $43K | |
| Q5108 | Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | <1% | 68 | $40K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 8,171 | $40K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,329 | $40K |
| 83690 | <1% | 5,623 | $39K | |
| 94726 | <1% | 660 | $39K | |
| 0510 | <1% | 2,433 | $39K | |
| 84520 | <1% | 11,577 | $39K | |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | <1% | 34 | $35K |
| 76770 | <1% | 420 | $35K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,327 | $35K |
| 86803 | <1% | 2,504 | $34K | |
| 90715 | <1% | 1,369 | $34K | |
| 93798 | <1% | 372 | $34K | |
| 82805 | <1% | 1,344 | $33K | |
| 73562 | <1% | 1,419 | $33K | |
| 0306 | <1% | 645 | $33K | |
| 87517 | <1% | 736 | $32K | |
| 73630 | <1% | 1,277 | $31K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 1,103 | $30K |
| 73130 | <1% | 1,230 | $30K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,036 | $30K |
| 82570 | <1% | 5,436 | $29K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 6,401 | $28K |
| 82465 | <1% | 5,524 | $28K | |
| 82550 | <1% | 3,734 | $28K | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 52 | $28K |
| 87340 | <1% | 2,727 | $28K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 89 | $28K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,629 | $27K |
| 88184 | <1% | 611 | $27K | |
| 85652 | <1% | 5,827 | $26K | |
| Z7502 | <1% | 749 | $26K | |
| 87186 | <1% | 2,841 | $26K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,057 | $25K |
| 86160 | <1% | 1,706 | $25K | |
| 83550 | <1% | 3,293 | $25K | |
| 83540 | <1% | 3,540 | $24K | |
| 85730 | <1% | 2,926 | $24K | |
| 73610 | <1% | 1,034 | $24K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,416 | $24K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 194 | $23K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 763 | $23K |
| 36430 | <1% | 226 | $23K | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 1,235 | $23K |
| 59425 | <1% | 372 | $22K | |
| 87088 | <1% | 3,308 | $22K | |
| 73030 | <1% | 972 | $22K | |
| 87077 | <1% | 3,399 | $22K | |
| 84439 | <1% | 2,783 | $21K | |
| 74018 | <1% | 731 | $21K | |
| 82977 | <1% | 2,489 | $21K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,191 | $21K |
| 87522 | Neg quan hep c or qual rna | <1% | 403 | $20K |
| 87536 | <1% | 265 | $19K | |
| 0270 | <1% | 6,821 | $19K | |
| 86592 | <1% | 3,374 | $18K | |
| 87070 | <1% | 1,455 | $17K | |
| 94618 | <1% | 380 | $17K | |
| 90662 | <1% | 1,000 | $16K | |
| 84156 | <1% | 3,292 | $16K | |
| 83520 | <1% | 967 | $16K | |
| 0160 | <1% | 123 | $16K | |
| 77301 | <1% | 57 | $16K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 929 | $15K |
| 86706 | <1% | 1,155 | $15K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 9,583 | $15K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 235 | $15K |
| Z9725 | <1% | 347 | $15K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 319 | $15K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 950 | $15K |
| 82746 | <1% | 1,296 | $15K | |
| 82607 | <1% | 1,767 | $14K | |
| 86360 | <1% | 386 | $14K | |
| 92557 | <1% | 475 | $14K | |
| 82330 | <1% | 1,505 | $14K | |
| A0429 | Emergency ambulance ride, basic life support | <1% | 506 | $14K |
| 86359 | <1% | 440 | $13K | |
| J7999 | Compounded drug, not otherwise classified | <1% | 625 | $13K |
| 77334 | <1% | 93 | $13K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,807 | $13K |
| 77300 | <1% | 82 | $13K | |
| 93976 | <1% | 104 | $13K | |
| 86704 | <1% | 944 | $13K | |
| 88342 | <1% | 230 | $13K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,259 | $13K |
| 93970 | <1% | 83 | $12K | |
| 82803 | <1% | 580 | $12K | |
| 85379 | <1% | 993 | $12K | |
| 86225 | <1% | 720 | $12K | |
| 0300 | <1% | 533 | $12K | |
| J9310 | Injection, rituximab, 100 mg | <1% | 16 | $12K |
| 90686 | <1% | 747 | $12K | |
| 93226 | <1% | 111 | $11K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 459 | $11K |
| 87205 | <1% | 2,373 | $11K | |
| Z6500 | <1% | 55 | $10K | |
| 96409 | <1% | 416 | $10K | |
| 87102 | <1% | 899 | $10K | |
| 93225 | <1% | 116 | $10K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 1,001 | $10K |
| 0305 | <1% | 819 | $10K | |
| 84165 | <1% | 938 | $10K | |
| 86235 | <1% | 309 | $10K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 98 | $9K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,061 | $9K |
| 86334 | <1% | 552 | $9K | |
| 84702 | <1% | 779 | $9K | |
| 97161 | <1% | 218 | $9K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 339 | $9K |
| 84550 | <1% | 1,785 | $8K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,568 | $8K |
| 87505 | <1% | 142 | $8K | |
| 82310 | <1% | 2,016 | $8K | |
| 73110 | <1% | 405 | $8K | |
| 0940 | <1% | 383 | $8K | |
| 82378 | <1% | 890 | $8K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 80 | $8K |
| 99221 | <1% | 226 | $8K | |
| 86635 | <1% | 361 | $7K | |
| 86923 | <1% | 178 | $7K | |
| 86038 | <1% | 558 | $7K | |
| 80195 | <1% | 673 | $7K | |
| 77338 | <1% | 64 | $7K | |
| 77336 | <1% | 180 | $7K | |
| 82077 | <1% | 877 | $7K | |
| 0720 | <1% | 230 | $7K | |
| 86787 | <1% | 546 | $7K | |
| 87486 | <1% | 288 | $7K | |
| 87581 | <1% | 293 | $7K | |
| 90677 | <1% | 56 | $7K | |
| 73590 | <1% | 357 | $7K | |
| 84145 | <1% | 404 | $7K | |
| 85007 | <1% | 1,617 | $7K | |
| 82962 | <1% | 2,388 | $7K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 240 | $6K |
| 82043 | <1% | 1,681 | $6K | |
| H1000 | Prenatal care, at-risk assessment | <1% | 53 | $6K |
| 73502 | <1% | 251 | $6K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 39 | $6K |
| 86255 | <1% | 201 | $6K | |
| J9370 | Vincristine sulfate, 1 mg | <1% | 472 | $6K |
| 84460 | <1% | 1,354 | $6K | |
| 87653 | <1% | 245 | $6K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,058 | $6K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 369 | $6K |
| 82232 | <1% | 646 | $6K | |
| 95700 | <1% | 36 | $6K | |
| 84450 | <1% | 1,308 | $6K | |
| 97116 | <1% | 386 | $5K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 620 | $5K |
| 92567 | <1% | 191 | $5K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 864 | $5K |
| 85384 | <1% | 451 | $5K | |
| 88341 | <1% | 29 | $5K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 157 | $5K |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 259 | $5K |
| 82610 | <1% | 538 | $5K | |
| 82247 | <1% | 1,241 | $5K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 531 | $5K |
| 82248 | <1% | 824 | $5K | |
| 83521 | <1% | 474 | $5K | |
| 84075 | <1% | 1,213 | $5K | |
| 87808 | <1% | 652 | $4K | |
| G0378 | Hospital observation service, per hour | <1% | 111 | $4K |
| 96416 | <1% | 20 | $4K | |
| C1769 | Guide wire | <1% | 89 | $4K |
| 85046 | <1% | 629 | $4K | |
| 85018 | <1% | 1,863 | $4K | |
| 88112 | <1% | 195 | $4K | |
| 96401 | <1% | 541 | $4K | |
| 70498 | <1% | 12 | $4K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 791 | $4K |
| Z6400 | <1% | 67 | $4K | |
| 88142 | <1% | 227 | $4K | |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 44 | $4K |
| 84403 | <1% | 407 | $4K | |
| 82150 | <1% | 447 | $4K | |
| 80143 | <1% | 368 | $4K | |
| 82670 | <1% | 203 | $4K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 97 | $4K |
| 86644 | <1% | 308 | $4K | |
| 92626 | <1% | 34 | $4K | |
| 86352 | <1% | 199 | $4K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 605 | $4K |
| G0008 | Administration of influenza virus vaccine | <1% | 976 | $4K |
| 0770 | <1% | 105 | $4K | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 53 | $3K |
| 76642 | <1% | 113 | $3K | |
| 82375 | <1% | 165 | $3K | |
| 86357 | <1% | 121 | $3K | |
| 59430 | <1% | 57 | $3K | |
| 86355 | <1% | 121 | $3K | |
| 93017 | <1% | 40 | $3K | |
| 0302 | <1% | 155 | $3K | |
| 84153 | <1% | 347 | $3K | |
| 96156 | <1% | 190 | $3K | |
| 93350 | <1% | 26 | $3K | |
| 91320 | <1% | 74 | $3K | |
| J2997 | Injection, alteplase recombinant, 1 mg | <1% | 16 | $3K |
| 82107 | <1% | 62 | $3K | |
| 86301 | <1% | 158 | $3K | |
| 86765 | <1% | 199 | $3K | |
| 0942 | <1% | 216 | $2K | |
| 90656 | <1% | 123 | $2K | |
| Z5910 | <1% | 51 | $2K | |
| 86708 | <1% | 128 | $2K | |
| 87206 | <1% | 410 | $2K | |
| 94621 | <1% | 12 | $2K | |
| 84425 | <1% | 365 | $2K | |
| H1002 | Prenatal care, at risk enhanced service; care coordination | <1% | 13 | $2K |
| 83050 | <1% | 164 | $2K | |
| 81003 | <1% | 886 | $2K | |
| 80179 | <1% | 196 | $2K | |
| 27500 | <1% | 29 | $2K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 165 | $2K |
| 84630 | <1% | 684 | $2K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 24 | $2K |
| 86665 | <1% | 125 | $2K | |
| 82533 | <1% | 122 | $2K | |
| 76870 | <1% | 44 | $2K | |
| 83001 | <1% | 105 | $2K | |
| 84134 | <1% | 83 | $2K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 30 | $2K |
| 76536 | <1% | 27 | $2K | |
| 86364 | <1% | 179 | $2K | |
| 87493 | <1% | 82 | $2K | |
| 0324 | <1% | 78 | $2K | |
| 92611 | <1% | 24 | $2K | |
| Z7506 | <1% | 16 | $2K | |
| 81025 | <1% | 347 | $2K | |
| 99152 | <1% | 82 | $1K | |
| 72100 | <1% | 54 | $1K | |
| 90480 | <1% | 69 | $1K | |
| 83951 | <1% | 26 | $1K | |
| 86682 | <1% | 128 | $1K | |
| 86480 | <1% | 40 | $1K | |
| X4540 | <1% | 40 | $1K | |
| 96402 | <1% | 321 | $1K | |
| 0272 | <1% | 211 | $1K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 111 | $1K |
| Z4302 | <1% | 95 | $1K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 104 | $1K |
| S0302 | Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) | <1% | 44 | $1K |
| 83655 | <1% | 207 | $1K | |
| 86645 | <1% | 86 | $1K | |
| 80074 | <1% | 15 | $1K | |
| H1003 | Prenatal care, at-risk enhanced service; education | <1% | 25 | $1K |
| Z7610 | <1% | 132 | $1K | |
| 86147 | <1% | 24 | $950.96 | |
| 86870 | <1% | 18 | $934.72 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 56 | $926.56 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 148 | $926.00 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 175 | $896.83 |
| G0009 | Administration of pneumococcal vaccine | <1% | 81 | $873.88 |
| 86762 | <1% | 68 | $871.06 | |
| 36600 | <1% | 13 | $858.22 | |
| A4649 | Surgical supply; miscellaneous | <1% | 461 | $856.55 |
| 86431 | <1% | 128 | $835.98 | |
| 84146 | <1% | 45 | $818.90 | |
| 82951 | <1% | 68 | $804.21 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 148 | $780.96 |
| 97162 | <1% | 12 | $769.88 | |
| 92522 | <1% | 13 | $757.92 | |
| 82785 | <1% | 59 | $747.70 | |
| 86376 | <1% | 51 | $736.85 | |
| 86800 | <1% | 52 | $711.34 | |
| 0307 | <1% | 61 | $686.00 | |
| 83883 | <1% | 91 | $676.08 | |
| 83010 | <1% | 61 | $669.02 | |
| J1836 | Injection, metronidazole, 10 mg | <1% | 16 | $661.49 |
| 86705 | <1% | 54 | $660.92 | |
| 86036 | <1% | 28 | $641.37 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 103 | $607.12 |
| 83002 | <1% | 36 | $603.24 | |
| 84481 | <1% | 42 | $581.17 | |
| 86777 | <1% | 26 | $577.16 | |
| 80158 | <1% | 86 | $565.68 | |
| 88313 | <1% | 16 | $556.48 | |
| 99401 | <1% | 62 | $529.86 | |
| 83993 | <1% | 49 | $527.91 | |
| 86880 | <1% | 54 | $497.10 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 72 | $487.43 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 132 | $460.13 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 52 | $449.78 |
| 82525 | <1% | 49 | $412.38 | |
| X4532 | <1% | 12 | $401.40 | |
| 76775 | <1% | 14 | $398.60 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 30 | $393.56 |
| 73090 | <1% | 46 | $381.59 | |
| 82040 | <1% | 83 | $360.52 | |
| 0771 | <1% | 12 | $350.64 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 18 | $347.38 |
| 92250 | <1% | 15 | $333.60 | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 19 | $330.50 |
| 89051 | <1% | 35 | $330.12 | |
| 81002 | <1% | 105 | $328.96 | |
| 73564 | <1% | 29 | $290.66 | |
| 82103 | <1% | 38 | $281.90 | |
| 73070 | <1% | 13 | $274.96 | |
| 82140 | <1% | 20 | $271.72 | |
| J9201 | Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | <1% | 22 | $258.61 |
| 86146 | <1% | 23 | $243.66 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 13 | $240.00 |
| 86258 | <1% | 27 | $230.36 | |
| 0124A | <1% | 14 | $221.82 | |
| 87116 | <1% | 17 | $219.87 | |
| 86304 | <1% | 15 | $216.39 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 13 | $200.96 |
| 96368 | <1% | 13 | $198.14 | |
| C9285 | Lidocaine 70 mg/tetracaine 70 mg, per patch | <1% | 13 | $198.08 |
| 73552 | <1% | 30 | $196.78 | |
| 81015 | <1% | 69 | $191.90 | |
| 86231 | <1% | 25 | $186.66 | |
| 96411 | <1% | 33 | $179.25 | |
| 88108 | <1% | 13 | $174.20 | |
| 83021 | <1% | 14 | $173.05 | |
| 85049 | <1% | 29 | $160.49 | |
| Z6406 | <1% | 13 | $156.78 | |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 12 | $146.10 |
| Z6410 | <1% | 12 | $144.72 | |
| 87075 | <1% | 15 | $133.72 | |
| 73560 | <1% | 31 | $131.50 | |
| 84300 | <1% | 29 | $129.52 | |
| 84132 | <1% | 25 | $127.51 | |
| 84295 | <1% | 13 | $125.48 | |
| 84157 | <1% | 12 | $122.46 | |
| 82435 | <1% | 13 | $119.83 | |
| 85613 | <1% | 12 | $115.98 | |
| 83921 | <1% | 14 | $114.33 | |
| 86300 | <1% | 30 | $103.16 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 27 | $102.44 |
| 86200 | <1% | 26 | $99.96 | |
| 87015 | <1% | 17 | $98.31 | |
| 84255 | <1% | 14 | $97.08 | |
| 86039 | <1% | 12 | $93.32 | |
| 96127 | <1% | 18 | $81.77 | |
| 84270 | <1% | 14 | $78.23 | |
| 82104 | <1% | 13 | $78.00 | |
| 84207 | <1% | 14 | $71.18 | |
| 87081 | <1% | 15 | $67.05 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 13 | $63.38 |
| 0637 | <1% | 95 | $53.58 | |
| 82085 | <1% | 13 | $53.36 | |
| 92558 | <1% | 40 | $30.00 | |
| 0780 | <1% | 18 | $28.00 | |
| 99072 | <1% | 155 | $10.40 | |
| 0260 | 0% | 12 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 13 | $0.00 |
| 0730 | 0% | 12 | $0.00 | |
| 0372 | 0% | 12 | $0.00 | |
| 0206 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWALLACE, TAMMY (CFO)
Parent organizationTHE REGENTS OF THE UNIVERSITY OF CALIFORNIA LOS ANGELES
| Provider | Location | Paid |
|---|---|---|
| Regents of the Univ of California | Santa Monica, CA | $11.54M |
| Regents of the University of | Panorama City, CA | $2.36M |
| Regents Univ of Calif Los Angeles | West Hills, CA | $360K |
| Regents Univ of Calif Los Angeles | Los Angeles, CA | $19K |
| DR Tammy Wallace LLC | Ozark, AL | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.